BioCentury
ARTICLE | Clinical News

Faropenem medoxomil: Phase III suspended enrollment

April 28, 2008 7:00 AM UTC

Replidyne discontinued enrollment in a placebo-controlled Phase III trial of oral faropenem, which had enrolled 475 of a planned 600 patients, in order to conserve cash. The AECB trial was 1 of 4 tria...